CDC NIOSH Studies To Evaluate RF Effect On Cell-Growth Substance
This article was originally published in The Gray Sheet
Executive Summary
The Centers for Disease Control and Prevention's National Institute for Occupational Health and Safety (NIOSH) is planning to evaluate ornithine decarboxylase (ODC), a substance associated with human cell growth induced by carcinogens.
You may also be interested in...
Mobile phones
Cellular Telecommunications Industry Association and FDA's device center ink a three-year cooperative R&D agreement June 8 that will facilitate third-party research on mobile phones as potential health hazards. Under the CRADA, an "organizing committee" of staff from CDRH and other agencies will oversee genotoxity and epidemiology studies intended to confirm earlier findings by Wireless Technology Research, LLC and assess the need for further research. CTIA will fund the research and cover FDA travel expenses
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.